Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer ...

Id1 and Id3 genes to confer poor prognosis in KRAS-mutant (KM) lung adenocarcinoma (LA) patients: Effect of gene silencing on metastatic rate to the liver and on survival. This is an ASCO Meeting ...

Please provide your email address to receive an email when new articles are posted on . The addition of pemetrexed plus platinum chemotherapy to the immune checkpoint inhibitor pembrolizumab showed ...

Please provide your email address to receive an email when new articles are posted on . “Sintilimab [Tyvyt; Eli Lilly & Co., Innovent Biologics] is a fully human IgG4 monoclonal antibody that blocks ...

Introduction: Malignant pleural mesothelioma (MPM) is a rapidly progressive tumor that is increasing in frequency worldwide. Treatment options are limited, and response to chemotherapy is poor. The ...

"The claim that pemetrexed is superior in adenocarcinoma is one that is not supported by the US FDA [US Food and Drug Administration] and is not supported by a careful consideration of the evidence," ...

The FDA has approved a generic form of the intravenous chemotherapy pemetrexed for use by itself in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not ...

The median OS was not reached at the time of the data cut-off in the pembrolizumab plus chemotherapy arm and was 11.3 months for those in the chemotherapy arm. The Food and Drug Administration (FDA) ...

Teva Pharmaceuticals (NYSE: TEVA) has a new treatment it can market. The company's Actavis Generics unit has been granted Food and Drug Administration (FDA) approval for its Pemetrexed chemotherapy ...

The three-drug combination of Tagrisso plus platinum-based chemotherapy and pemetrexed boosted outcomes for patients with EGFR-mutant advanced non-small cell lung cancer. Tagrisso(osimertinib) ...